When to use stem cell transplantation for classical Hodgkin lymphoma

2.

Younes

A

,

Gopal

AK

,

Smith

SE

, et al.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

.

J Clin Oncol

.

2012

;

30

(

18

):

2183

-

2189

.

3.

Moskowitz

CH

,

Nademanee

A

,

Masszi

T

, et al;

AETHERA Study Group

.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

.

Lancet

.

2015

;

385

(

9980

):

1853

-

1862

.

4.

Gopal

AK

,

Chen

R

,

Smith

SE

, et al.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

.

Blood

.

2015

;

125

(

8

):

1236

-

1243

.

5.

Armand

P

,

Ansell

SM

,

Lesokhin

AM

, et al.

Nivolumab in patients with relapsed or refractory Hodgkin lymphoma—preliminary safety, efficacy and biomarker results of a phase I study

.

Blood

.

2014

;

124

(

21

):

289

.

6.

Armand

P

,

Engert

A

,

Younes

A

, et al.

Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial

.

J Clin Oncol

.

2018

;

36

(

14

):

1428

-

1439

.

7.

Armand

P

,

Shipp

MA

,

Ribrag

V

, et al.

Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure

.

J Clin Oncol

.

2016

;

34

(

31

):

3733

-

3739

.

8.

Chen

R

,

Zinzani

PL

,

Fanale

MA

, et al;

KEYNOTE-087

.

Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma

.

J Clin Oncol

.

2017

;

35

(

19

):

2125

-

2132

.

9.

Perales

MA

,

Ceberio

I

,

Armand

P

, et al;

American Society for Blood and Marrow Transplantation

.

Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation

.

Biol Blood Marrow Transplant

.

2015

;

21

(

6

):

971

-

983

.

10.

Alvarez

I

,

Sureda

A

,

Caballero

MD

, et al.

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol

.

Biol Blood Marrow Transplant

.

2006

;

12

(

2

):

172

-

183

.

11.

Shah

NN

,

Hamadani

M.

Is there still a role for allogeneic transplantation in the management of lymphoma?

J Clin Oncol

.

2021

;

39

(

5

):

487

-

498

.

12.

Ahmed

S

,

Kanakry

JA

,

Ahn

KW

, et al.

Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma

.

Biol Blood Marrow Transplant

.

2019

;

25

(

9

):

1859

-

1868

.

13.

Ahmed

S

,

Ghosh

N

,

Ahn

KW

, et al.

Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

.

Br J Haematol

.

2020

;

190

(

4

):

573

-

582

.

14.

Younes

A

,

Santoro

A

,

Shipp

M

, et al.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

.

Lancet Oncol

.

2016

;

17

(

9

):

1283

-

1294

.

15.

Chen

R

,

Zinzani

PL

,

Lee

HJ

, et al.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

.

Blood

.

2019

;

134

(

14

):

1144

-

1153

.

16.

Moskowitz

AJ

,

Shah

G

,

Schöder

H

, et al.

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

.

J Clin Oncol

.

2021

;

39

(

28

):

3109

-

3117

.

17.

Moskowitz

AJ

.

Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?

Hematology Am Soc Hematol Educ Program

.

2022

;

2022

(

1

):

699

-

705

.

18.

Ramchandren

R

,

Domingo-Domènech

E

,

Rueda

A

, et al.

Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study

.

J Clin Oncol

.

2019

;

37

(

23

):

1997

-

2007

.

19.

Bröckelmann

PJ

,

Engert

A.

Checkpoint inhibition in Hodgkin lymphoma—a review

.

Oncol Res Treat

.

2017

;

40

(

11

):

654

-

660

.

20.

Herrera

AF

,

Moskowitz

AJ

,

Bartlett

NL

, et al.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

.

Blood

.

2018

;

131

(

11

):

1183

-

1194

.

21.

Josting

A

,

Müller

H

,

Borchmann

P

, et al.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma

.

J Clin Oncol

.

2010

;

28

(

34

):

5074

-

5080

.

22.

Adams

HJ

,

Kwee

TC

.

Prognostic value of pretransplant FDG-PET in refractory/ relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis

.

Ann Hematol

.

2016

;

95

(

5

):

695

-

706

.

23.

Desai

SH

,

Spinner

MA

,

David

K

, et al.

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma

.

Am J Hematol

.

2023

;

98

(

3

):

464

-

471

.

24.

Chen

R

,

Palmer

JM

,

Martin

P

, et al.

Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma

.

Biol Blood Marrow Transplant

.

2015

;

21

(

12

):

2136

-

2140

.

25.

Garcia-Sanz

R

,

Sureda

A

,

de la Cruz

F

, et al.

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

.

Ann Oncol

.

2019

;

30

(

4

):

612

-

620

.

26.

Lynch

RC

,

Cassaday

RD

,

Smith

SD

, et al.

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase ½ study

.

Lancet Haematol

.

2021

;

8

(

8

):

e562

-

e571

.

27.

Kersten

MJ

,

Driessen

J

,

Zijlstra

JM

, et al.

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

.

Haematologica

.

2021

;

106

(

4

):

1129

-

1137

.

28.

LaCasce

AS

,

Bociek

RG

,

Sawas

A

, et al.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

.

Blood

.

2018

;

132

(

1

):

40

-

48

.

29.

Advani

RH

,

Moskowitz

AJ

,

Bartlett

NL

, et al.

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

.

Blood

.

2021

;

138

(

6

):

427

-

438

.

30.

Mei

MG

,

Lee

HJ

,

Palmer

JM

, et al.

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

.

Blood

.

2022

;

139

(

25

):

3605

-

3616

.

31.

Linch

DC

,

Winfield

D

,

Goldstone

AH

, et al.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

.

Lancet

.

1993

;

341

(

8852

):

1051

-

1054

.

32.

Schmitz

N

,

Pfistner

B

,

Sextro

M

, et al;

German Hodgkin's Lymphoma Study Group

;

Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

.

Lancet

.

2002

;

359

(

9323

):

2065

-

2071

.

33.

Rancea

M

,

Monsef

I

,

von Tresckow

B

,

Engert

A

,

Skoetz

N.

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma

.

Cochrane Database Syst Rev

.

2013

;

6

:

CD009411

.

34.

Sieniawski

M

,

Franklin

J

,

Nogova

L

, et al.

Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma

.

J Clin Oncol

.

2007

;

25

(

15

):

2000

-

2005

.

35.

Stoneham

S

,

Ashley

S

,

Pinkerton

CR

,

Wallace

WH

,

Shankar

AG

;

United Kingdom Children's Cancer Study Group

.

Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease

.

J Pediatr Hematol Oncol

.

2004

;

26

(

11

):

740

-

745

.

36.

Schellong

G

,

Dörffel

W

,

Claviez

A

, et al;

DAL/GPOH Study Group

.

Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group

.

J Clin Oncol

.

2005

;

23

(

25

):

6181

-

6189

.

37.

Bachier

C

,

Schade

H

,

Zoghi

B

,

Ramakrishnan

A

,

Shah

NN

.

A phase II single arm study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression

.

Blood

.

2021

;

138

(

suppl 1

):

2455

.

38.

Armand

P

,

Chen

YB

,

Redd

RA

, et al.

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

.

Blood

.

2019

;

134

(

1

):

22

-

29

.

39.

Herrera

AF

,

Chen

L

,

Nieto

Y

, et al.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

1

):

e14

-

e23

.

40.

Sarina

B

,

Castagna

L

,

Farina

L

, et al;

Gruppo Italiano Trapianto di Midollo Osseo

.

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

.

Blood

.

2010

;

115

(

18

):

3671

-

3677

.

41.

Martínez

C

,

Canals

C

,

Sarina

B

, et al;

Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

;

Gruppo Italiano Trapianto di Midollo Osseo

.

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

.

Ann Oncol

.

2013

;

24

(

9

):

2430

-

2434

.

42.

Sureda

A

,

Canals

C

,

Arranz

R

, et al.

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

.

Haematologica

.

2012

;

97

(

2

):

310

-

317

.

43.

Anderlini

P

,

Saliba

R

,

Acholonu

S

, et al.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

.

Haematologica

.

2008

;

93

(

2

):

257

-

264

.

44.

Robinson

SP

,

Sureda

A

,

Canals

C

, et al;

Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

.

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

.

Haematologica

.

2009

;

94

(

2

):

230

-

238

.

45.

Devetten

MP

,

Hari

PN

,

Carreras

J

, et al.

Unrelated donor reduced- intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

.

Biol Blood Marrow Transplant

.

2009

;

15

(

1

):

109

-

117

.

46.

Gauthier

J

,

Castagna

L

,

Garnier

F

, et al.

Reduced-intensity and non- myeloablative allogeneic stem cell transplantation from alternative HLA- mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

.

Bone Marrow Transplant

.

2017

;

52

(

5

):

689

-

696

.

47.

Kako

S

,

Izutsu

K

,

Kato

K

, et al;

Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation

.

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

.

Am J Hematol

.

2015

;

90

(

2

):

132

-

138

.

48.

Castagna

L

,

Busca

A

,

Bramanti

S

, et al.

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients

.

BMC Cancer

.

2020

;

20

(

1

):

1140

.

49.

Montoro

J

,

Boumendil

A

,

Finel

H

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis in HLA-matched and haploidentical donor transplantation for patients with Hodgkin lymphoma: a comparative study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

.

Transplant Cell Ther

.

2024

;

30

(

2

):

210.e1

-

210210.e14

.

50.

Hegerova

L

,

Cao

Q

,

Lazaryan

A

, et al.

Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era

.

Bone Marrow Transplant

.

2017

;

52

(

5

):

697

-

703

.

51.

Bazarbachi

A

,

Boumendil

A

,

Finel

H

, et al.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party

.

Br J Haematol

.

2018

;

181

(

1

):

86

-

96

.

52.

Ijaz

A

,

Khan

AY

,

Malik

SU

, et al.

Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation

.

Biol Blood Marrow Transplant

.

2019

;

25

(

1

):

94

-

99

.

53.

Merryman

RW

,

Kim

HT

,

Zinzani

PL

, et al.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/ refractory lymphoma

.

Blood

.

2017

;

129

(

10

):

1380

-

1388

.

54.

Merryman

RW

,

Castagna

L

,

Giordano

L

, et al.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

.

Leukemia

.

2021

;

35

(

9

):

2672

-

2683

.

55.

De Philippis

C

,

Legrand-Izadifar

F

,

Bramanti

S

, et al.

Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma

.

Blood Adv

.

2020

;

4

(

7

):

1242

-

1249

.

56.

Rashidi

A

,

Ebadi

M

,

Cashen

AF

.

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

.

Bone Marrow Transplant

.

2016

;

51

(

4

):

521

-

528

.

57.

Milpied

N

,

Fielding

AK

,

Pearce

RM

,

Ernst

P

,

Goldstone

AH

;

European Group for Blood and Bone Marrow Transplantation

.

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease

.

J Clin Oncol

.

1996

;

14

(

4

):

1291

-

1296

.

58.

Freytes

CO

,

Loberiza

FR

,

Rizzo

JD

, et al;

Lymphoma Working Committee of the International Bone Marrow Transplant Registry

.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry

.

Blood

.

2004

;

104

(

12

):

3797

-

3803

.

59.

Genadieva-Stavrik

S

,

Boumendil

A

,

Dreger

P

, et al.

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

.

Ann Oncol

.

2016

;

27

(

12

):

2251

-

2257

.

60.

Ghosh

N

,

Ahmed

S

,

Ahn

KW

, et al.

Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant

.

JAMA Oncol

.

2020

;

6

(

7

):

1011

-

1018

.

61.

Gauthier

J

,

Poiré

X

,

Gac

AC

, et al.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

.

Bone Marrow Transplant

.

2018

;

53

(

4

):

400

-

409

.

62.

Martínez

C

,

Gayoso

J

,

Canals

C

, et al;

Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

.

Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

.

J Clin Oncol

.

2017

;

35

(

30

):

3425

-

3432

.

63.

Burroughs

LM

,

O'Donnell

PV

,

Sandmaier

BM

, et al.

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

.

Biol Blood Marrow Transplant

.

2008

;

14

(

11

):

1279

-

1287

.

64.

Mussetti

A

,

Sureda

A.

Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin's lymphoma with posttransplant cyclophosphamide

.

Bone Marrow Transplant

.

2020

;

55

(

3

):

483

-

484

.

65.

Mussetti

A

,

Kanate

AS

,

Wang

T

, et al.

Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas

.

Transplant Cell Ther

.

2023

;

29

(

3

):

184.e1

-

184184.e9

.

66.

Shaw

BE

,

Jimenez-Jimenez

AM

,

Burns

LJ

, et al.

National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

.

J Clin Oncol

.

2021

;

39

(

18

):

1971

-

1982

.

67.

Jimenez-Jimenez

AM

,

Komanduri

K

,

Brown

S

, et al.

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant

.

Blood Adv

.

2022

;

6

(

15

):

4491

-

4500

.

68.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al;

BMT CTN 1703 Investigators

.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.